Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

PONSTAN 250 MG

MEFENAMIC ACID : 250 MG · DIN 00155225 · AA PHARMA INC

Health Canada status: DORMANT

What is PONSTAN?

PONSTAN 250 MG contains MEFENAMIC ACID : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00155225, held by AA PHARMA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is PONSTAN used for?

PONSTAN (mefenamic acid) is indicated for the relief of pain of moderate severity in conditions such as muscular aches and pains, primary dysmenorrhea, headache, and dental pain. It only relieves symptoms and decreases inflammation for as long as the patient continues to take it.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN00155225
Brand namePONSTAN
Generic / active ingredientMEFENAMIC ACID : 250 MG
ManufacturerAA PHARMA INC
Strength250 MG
Dosage formCAPSULE
Route of administrationORAL
SchedulePrescription
ATC codeM01AG01 MEFENAMIC ACID
BiosimilarNo
Health Canada statusDORMANT
Status date31-Jul-2019
Original market date1965-12-31 00:00:00

How is it stored and handled?

null

How is it supplied?

Bottle of 100’s

Is MEFENAMIC ACID in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for PONSTAN

What can be used instead?

Other Canadian products sharing ATC code M01AG01 MEFENAMIC ACID. 1 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
MEFENAMIC250 MGCAPSULEAA PHARMA INCMARKETEDDIN 02229452
DOM-MEFENAMIC ACID250 MGCAPSULEDOMINION PHARMACALCANCELLED POST MARKETDIN 02237826
MEFENAMIC ACID250 MGCAPSULEAPOTEX INCAPPROVEDDIN 02229569
MEFENAMIC-250250 MGCAPSULEPRO DOC LIMITEECANCELLED POST MARKETDIN 02230408
NOVO-MEFENAMIC CAPSULES 250MG250 MGCAPSULENOVOPHARM LIMITEDCANCELLED PRE MARKETDIN 02239836
PMS-MEFENAMIC ACID250 MGCAPSULEPHARMASCIENCE INCCANCELLED POST MARKETDIN 02231208

Who else supplies MEFENAMIC ACID worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. MEFENAMIC ACID appears in 75 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.

Ask about sourcing PONSTAN

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 00155225. Last reviewed 2026-09-09. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.